Literature DB >> 20921949

Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats.

Cheng Liu1, Qing Tao, Mingyu Sun, Jim Z Wu, Wengang Yang, Ping Jian, Jinghua Peng, Yiyang Hu, Chenghai Liu, Ping Liu.   

Abstract

Hepatocellular apoptosis, hepatic inflammation, and fibrosis are prominent features in chronic liver diseases. However, the linkage among these processes remains mechanistically unclear. In this study, we examined the apoptosis and activation of Kupffer cells (KCs) as well as their pathophysiological involvement in liver fibrosis process. Hepatic fibrosis was induced in rats by dimethylnitrosamine (DMN) or carbon tetrachloride (CCl4) treatment. KCs were isolated from normal rats and incubated with lipopolysaccharide (LPS) or from fibrotic rats. The KCs were stained immunohistochemically with anti-CD68 antibody, a biomarker for KC. The level of expression of CD68 was analyzed by western blot and real-time PCR methods. The apoptosis and pathophysiological involvement of KCs in the formation of liver fibrosis were studied using confocal microscopy. The mRNA and protein expression of CD68 were significantly increased in DMN- and CCL4-treated rats. Confocal microscopy analysis showed that CD68-positive KCs, but not α-smooth muscle actin (SMA)-positive cells, underwent apoptosis in the liver of DMN- and CCL4-treated rats. It was also revealed that the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling and CD68-double-positive apoptotic KCs located in the portal or fibrotic septa area were situated next to hepatic stellate cells (HSCs). Tumor necrosis factor-α (TNF-α) and KC co-localized in the liver in the neighbor of HSCs. The double α-SMA- and collagen type I-positive cells predominantly existed in fibrotic septa, and those cells were co-localized clearly with CD68-positive cells. Interestingly, some CD68 and Col (1) double positive, but completely negative for α-SMA, were found in the portal areas and hepatic sinusoids; this phenomenon was also validated in primary isolated KCs after 6 h LPS exposure or fibrotic rats in vitro. These results show that KCs are associated with hepatocellular apoptosis, inflammation, and fibrosis process in a liver fibrosis models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20921949     DOI: 10.1038/labinvest.2010.123

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  51 in total

1.  Role of ceramides in nonalcoholic fatty liver disease.

Authors:  Mangesh Pagadala; Takhar Kasumov; Arthur J McCullough; Nizar N Zein; John P Kirwan
Journal:  Trends Endocrinol Metab       Date:  2012-05-17       Impact factor: 12.015

2.  TNFα in liver fibrosis.

Authors:  Yoon Mee Yang; Ekihiro Seki
Journal:  Curr Pathobiol Rep       Date:  2015-09-30

Review 3.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

4.  Transcriptional repression of the transforming growth factor β (TGF-β) Pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) by Nuclear Factor κB (NF-κB) p50 enhances TGF-β signaling in hepatic stellate cells.

Authors:  Cheng Liu; Xiaorong Chen; Ling Yang; Tatiana Kisseleva; David A Brenner; Ekihiro Seki
Journal:  J Biol Chem       Date:  2014-01-21       Impact factor: 5.157

5.  Angiotensin II facilitates fibrogenic effect of TGF-β1 through enhancing the down-regulation of BAMBI caused by LPS: a new pro-fibrotic mechanism of angiotensin II.

Authors:  Yu-Sheng Li; Shu-Yuan Ni; Ying Meng; Xiao-Lan Shi; Xu-Wen Zhao; Hai-Hua Luo; Xu Li
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

6.  Deregulated neddylation in liver fibrosis.

Authors:  Imanol Zubiete-Franco; Pablo Fernández-Tussy; Lucía Barbier-Torres; Jorge Simon; David Fernández-Ramos; Fernando Lopitz-Otsoa; Virginia Gutiérrez-de Juan; Sergio López de Davalillo; Antonio Martín Duce; Paula Iruzubieta; Daniel Taibo; Javier Crespo; Juan Caballeria; Erica Villa; Igor Aurrekoetxea; Patricia Aspichueta; Marta Varela-Rey; Shelly C Lu; José M Mato; Naiara Beraza; Teresa C Delgado; María L Martínez-Chantar
Journal:  Hepatology       Date:  2016-12-30       Impact factor: 17.425

Review 7.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

8.  A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice.

Authors:  Mei Yee Koh; Mihai Gagea; Timothy Sargis; Robert Lemos; Geoffrey Grandjean; Adriana Charbono; Vasileos Bekiaris; John Sedy; Galina Kiriakova; Xiuping Liu; Lewis R Roberts; Carl Ware; Garth Powis
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425

9.  Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin.

Authors:  Mari Saif; Wilhelmus J Kwanten; Jessica A Carr; Ivy X Chen; Jessica M Posada; Amitabh Srivastava; Juanye Zhang; Yi Zheng; Matthias Pinter; Sampurna Chatterjee; Samir Softic; C Ronald Kahn; Klaus van Leyen; Oliver T Bruns; Rakesh K Jain; Moungi G Bawendi
Journal:  Nat Biomed Eng       Date:  2020-06-22       Impact factor: 25.671

10.  A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.

Authors:  Gautam Mehta; Sam Rousell; Gary Burgess; Mark Morris; Gavin Wright; Stuart McPherson; Catherine Frenette; Matthew Cave; David T Hagerty; Alfred Spada; Rajiv Jalan
Journal:  J Clin Exp Hepatol       Date:  2017-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.